Long-term Safety of Ketoconazole Foam, 2% in the Treatment of Seborrheic Dermatitis: Results of a Phase IV, Open-Label Study

January 2013 | Volume 12 | Issue 1 | Original Article | 1 | Copyright © January 2013


Zoe D. Draelos MD a, Steven R. Feldman MD PhD b, Victoria Butners BSc c, and Alessandra B. Alió Saenz MD c

aDepartment of Dermatology, Duke University School of Medicine, Durham, NC bDepartment of Dermatology, Wake Forest University, Winston-Salem, NC cStiefel, a GlaxoSmithKline (GSK) company, Research Triangle Park, NC